Bach Institute of Biochemistry, Federal Research Centre "Fundamentals of Biotechnology" of the Russian Academy of Sciences, 119071 Moscow, Russia.
Department of Chemistry, Interdisciplinary Scientific and Educational School of Moscow University "Brain, Cognitive Systems, Artificial Intelligence", Lomonosov Moscow State University, 119991 Moscow, Russia.
Int J Mol Sci. 2022 Dec 22;24(1):176. doi: 10.3390/ijms24010176.
Penicillin-binding proteins 2 (PBP2) are critically important enzymes in the formation of the bacterial cell wall. Inhibition of PBP2 is utilized in the treatment of various diseases, including gonorrhea. Ceftriaxone is the only drug used to treat gonorrhea currently, and recent growth in PBP2 resistance to this antibiotic is a serious threat to human health. Our study reveals mechanistic aspects of the inhibition reaction of PBP2 from the wild-type FA19 strain and mutant 35/02 and H041 strains of by ceftriaxone. QM(PBE0-D3/6-31G**)/MM MD simulations show that the reaction mechanism for the wild-type PBP2 consists of three elementary steps including nucleophilic attack, C-N bond cleavage in the β-lactam ring and elimination of the leaving group in ceftriaxone. In PBP2 from the mutant strains, the second and third steps occur simultaneously. For all considered systems, the acylation rate is determined by the energy barrier of the first step that increases in the order of PBP2 from FA19, 35/02 and H041 strains. Dynamic behavior of ES complexes is analyzed using geometry and electron density features including Fukui electrophilicity index and Laplacian of electron density maps. It reveals that more efficient activation of the carbonyl group of the antibiotic leads to the lower energy barrier of nucleophilic attack and larger stabilization of the first reaction intermediate. Dynamical network analysis of MD trajectories explains the differences in ceftriaxone binding affinity: in PBP2 from the wild-type strain, the β-β loop conformation facilitates substrate binding, whereas in PBP2 from the mutant strains, it exists in the conformation that is unfavorable for complex formation. Thus, we clarify that the experimentally observed decrease in the second-order rate constant of acylation (/) in PBP2 from the mutant strains is due to both a decrease in the acylation rate constant and an increase in the dissociation constant .
青霉素结合蛋白 2(PBP2)是细菌细胞壁形成过程中至关重要的酶。抑制 PBP2 被用于治疗各种疾病,包括淋病。头孢曲松是目前唯一用于治疗淋病的药物,而最近 PBP2 对这种抗生素的耐药性增长对人类健康构成了严重威胁。我们的研究揭示了野生型 FA19 菌株和突变体 35/02 和 H041 菌株的 PBP2 与头孢曲松的抑制反应的机制方面。QM(PBE0-D3/6-31G**)/MM MD 模拟表明,野生型 PBP2 的反应机制包括三个基本步骤,包括亲核攻击、β-内酰胺环中的 C-N 键断裂和头孢曲松中离去基团的消除。在突变株的 PBP2 中,第二和第三步同时发生。对于所有考虑的系统,酰化速率由第一步的能量势垒决定,该势垒按 FA19、35/02 和 H041 菌株的 PBP2 顺序增加。使用几何形状和电子密度特征(包括福井亲电指数和电子密度图的拉普拉斯)分析 ES 复合物的动态行为。结果表明,抗生素羰基的更有效激活导致亲核攻击的能量势垒降低,并且第一反应中间体的稳定性增加。MD 轨迹的动力学网络分析解释了头孢曲松结合亲和力的差异:在野生型菌株的 PBP2 中,β-β 环构象有利于底物结合,而在突变株的 PBP2 中,它存在于不利于复合物形成的构象。因此,我们澄清了实验观察到的突变株的 PBP2 中酰化的二级速率常数(/)降低是由于酰化速率常数 和离解常数 都降低。